Expert Video - Which MDS genetic mutations are most likely to cause relapse?

Valeria Santini, MD, an expert on MDS and Associate Professor of Hematology at the University of Florence, describes how some mutations, such as a mutation on the TP53 gene, are linked to a greater likelihood of relapse after MDS treatment. She discusses the effect of having several mutations and how mutations arising during the course of myelodysplastic syndromes (MDS) can lead to treatment resistance.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.

Please rate this content:
 

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.